The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
NCT05938712 on ClinicalTrials.gov · last registry update 2026-05-01
A small phase 2 — 20 participants, against a typical 110. Due to report 1 October 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Proximal tubular natriuresis with combination therapy. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 24 October 2023 — 3 years so far.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 20
- Started
- 2023-10-24
- Primary completion
- 2027-10-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proximal tubular natriuresis with combination therapy
Conditions studied
Kidney Transplant Recipients
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.